Nutritional Programming of Probiotics to Promote Health and Well-Being by Elad, Alice Maayan & Lesmes, Uri
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2 
 
 
 
 
© 2012 Elad and Lesmes, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Nutritional Programming of Probiotics  
to Promote Health and Well-Being 
Alice Maayan Elad and Uri Lesmes 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50051 
1. Introduction 
The human large intesine is inhabited by a diverse and complex bacterial flora, which 
includes an outstanding total number of 1014 cells, >1000 species and a biomass of more than 
1 kg [1, 2]. Thus, the gut microbiota may be conceived as a specialized 'microbial organ' 
within the gut, affecting human health and disease through its involvement in pathogenesis, 
nutrition and immunity of the host [1-3]. Recently it has also been recognized that this 
dynamic yet stable ecosystem plays a role in conditions such as obesity and diabetes as well 
as in general well-being, from infancy to ageing [1-8]. Consequently, an increasing number 
of studies which explore the potential of promoting health by nutrition focuses on possible 
ways to influence and modulate the composition and activity of the gut flora towards a 
healthier one [4, 9-12]. 
In this respect, three major dietary approaches have been studied and applied. The first 
approach of probiotics is to fortify the gut flora through the consumption of exogenous live 
microorganisms, e.g. L. acidophilus in dairy products. The second strategy of prebiotics seeks 
to selectively stimulate the growth and/or activity of one or a limited number of 
advantageous indigenous bacteria in the host gut flora [1, 13]. The third approach, known as 
synbiotics due to its synergistic nature, aims to combine the previous ones by the 
simultaneous administration of probiotics and prebiotics, which improves the survival and 
implantation of the live microbes [13].  
Over the years, much attention has been drawn to indigestible carbohydrates that evade 
enzymatic digestion in the upper gastrointestinal tract and become available for 
fermentation in the colon [13]. These dietary compounds were later termed as prebiotics, a 
definition of which has been updated into its current form as "a selectively fermented 
ingredient that allows specific changes, both in the composition and/or activity in the 
gastrointestinal microflora that confers benefits upon host well-being and health" [14, 15]. 
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Although a more recent development compared to probiotics, prebiotics have been at the 
heart of various studies and numerous commercial products since they do not share the 
problem of probiotic survival upon ingestion by the consumer, and they can be added to a 
broad range of food products (e.g. confectionary and baked foods as well as more traditional 
fermented milk products and fruit drinks) because the majority of prebiotics are 
carbohydrates [16]. 
Amongst the carbohydrates currently marketed as prebiotics, inulin, fructo-oligosaccharides 
(FOS), galacto-oligosaccharides (GOS) and lactulose are consistently supported by high 
quality data from in vitro, in vivo and human trials [10-12, 14, 16-19]. Specifically, human 
trials have established that dietary consumption of 5-20 g/day of these prebiotics stimulates 
the growth of Bifidobacterium and Lactobacillus and promotes the health and well-being of 
infants, adults, pregnant and lactating women as well as the elderly to varying extents [6, 8, 
11, 20, 21]. 
2. Prebiotics as gut flora management tools 
2.1. Established prebiotics 
Overall, three major groups of compounds have been consistently established as prebiotics 
conferring health benefits (as detailed in Table 1): fructans, which include inulin and fructo-
oligosaccharides (FOS), galacto-oligosaccharides and lactulose. Under the general term 
fructans one can classify three established prebiotic carbohydrates: inulin, fructo-
oligosaccharides (FOS) and short chain fructo-oligosaccharides (scFOS) [16-18]. The fructans 
are polymers composed of D-fructose units joined by β-2-1 glycosidic linkages and 
terminated by an α-1-2-linked D-glucose.  
 
Established 
prebiotic 
Recommended 
efficaceous 
intake [g/day] 
Key effects in 
humans 
Potential 
adverse intake 
[g/day] 
Suggested 
references 
Inulin 5-15  Stimulate 
bifidobacteria 
growth 
 Production of 
short chain fatty 
acids 
 Protection 
against enteric 
infections 
> 15 (increase in 
fecal output) 
[22] 
Fructo-
oligosaccharides 
10-15 > 15 (increase in 
fecal output)  
[17] 
Galacto-
oligosaccharides 
10-15 > 20 g/human 
body (diarrhea)  
[19] 
Lactulose 10  > 20 (laxative)  [23] 
Table 1. The main established prebiotics and their beneficial/adverse intakes. 
The degree of polymerization (DP), defined by the number of monosaccharide units, is used 
to distinguish between inulin, FOS and scFOS. Molecules with a DP between 2-60 are 
referred to as inulin. Inulin is commercially produced from chicory roots, but it is present in 
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varying extent also in onions, garlic, Jerusalem artichoke, tomato and banana [11, 16, 21]. 
Similarly, oligofructose, commonly referred to as FOS, is prepared from chicory in an 
enzymatic hydrolysis using inulinase, and defined as oligosaccharide fractions which have a 
maximal DP of 20 with most common commercial products having an average DP of 9. In 
contrast, scFOS are synthesized in an enzymatic reaction via transfer of fructosyl units from 
sucrose molecules to yield mixtures of fructosyl chains with a maximum DP of 5. The 
mixture produced is usually comprised mainly of 1-kestose (2 units of fructose linked to 
glucose, GF2), nystose (GF3) and 1-fructosyl nystose (GF4) [16, 17, 24]. 
Fructans have a long tradition as prebiotics. Since their fructose units are joined by β-
linkages, they are resistant to hydrolysis by the human digestive enzymes which mainly 
cleave α-linkages. As a consequence, when these carbohydrates reach the colon they 
selectively stimulate the growth of beneficial bacteria such as bifidobacteria, which do 
contain specific enzymes for their degradation, i.e. β-fructosidases [16, 21, 25]. Therefore, 
inulin, FOS and scFOS are classified as 'nondigestible' carbohydrates, with a calorie value of 
1.5-2.0 kcal/g [24]. FOS fermentation in the colon results in increased levels of short chain 
fatty acids (SCFA) which lower the pH in the intestinal lumen. This can provide an 
explanation to the reports that these fructans lead to a decrease in the number of harmful 
bacteria in the colon (such as Clostridium, Streptococcus faecallis and Escherichia coli) [21, 25]. 
Galacto-oligosaccharides (GOS) are galactose-containing oligosaccharide mixtures of the 
form Glu α-1-4[β-Gal-1-6]n where n can be between two to five. They are produced from 
lactose syrup using β-galactosidases, which catalyze the hydrolysis of lactose into glucose 
and galactose, and also the transgalactosylation reactions with lactose as acceptor of 
galactose units giving rise to a variety of glycosidic linkages and molecular weights [11, 16, 
19, 21]. Furthermore, the use of different enzymes in the various production processes of 
GOS leads to variability in their purity and glycosidic linkages, with β-1-6, β-1-3 and β-1-4 
being the dominant [19]. Several in vitro and in vivo experiments have demonstrated that as 
in inulin-type fructans, the β-glycosidic linkages in GOS render them resistant to hydrolysis 
by the human digestive enzymes secreted in the upper gastrointestinal tract [16, 19, 21, 26]. 
In light of that, manufacturers are obliged by the European regulation to clearly identify 
GOS-containing food products as dietary fibers, with an estimated low calorie value of 1-2 
kcal/g [19]. 
Most of the health effects related to GOS arise from their selective fermentation by 
bifidobacteria and lactobacilli. In fact, it has been reported that when added to infant milk 
formulas, these oligosaccharides replicated the bifidogenic effect of human breast milk, not 
only in bacterial counts, but also with respect to the metabolic activity of the microflora in 
the colon [16, 27]. The growth of Lactobacillus paracasei and Bifidobacterium lactis has been 
shown to be preferential when grown on tri- and tetrasaccharide fractions of FOS or GOS, 
which supports the notion that prebiotics selectively promote the proliferation of bacteria 
possesing an active transport system enabling them to utilize these oligosaccharides [28-30]. 
In addition, it has been demonstrated that GOS compete for pathogen binding sites that coat 
the surface of the gastrointestinal epithelial cells [31, 32]. 
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Finally, lactulose (β-1-4-galactosyl-fructose) is a synthetic disaccharide derived from lactose. 
It is commonly used as a laxative in pharmaceutical products for the treatment of 
constipation, in doses over 20 g/day [16, 21]. Nevertheless, human trials have shown that at 
lower doses, lactulose acts as a prebiotic, reaching the colon and increasing bifidobacteria 
counts [2, 16, 17, 23]. Although this substance is an established prebiotic, it is still heavily 
confined to applications as a therapeutic agent. 
2.2. Novel prebiotics 
The search for new and novel prebiotics is constantly driven by the increased interest in 
management of human health through nutrition, particularly by the modulation of gut flora. 
In addition, studies of established prebiotics have enabled the better understanding of 
mechanisms of action and properties, which provided the basis for emerging prebiotics. 
Among the large array of prebiotic candidates, isomalto-oligosaccharides (IMO), xylo-
oligosaccharides (XOS), soy-oligosaccharides (SOS), gluco-oligosaccharides, lactosucrose 
and resistant starches can be classified as emerging prebiotics [17, 33-40]. Some of these 
compounds present advantages over established prebiotics; for example, XOS are stable 
across a wide range of pH, hence they are resistant to degradation in low pH juices, in 
contrast to inulin [21]. Besides attempts to identify and isolate naturally occurring prebiotics 
there are also attempts to enhance and extend the functionality of exisiting natural 
prebiotics through a rational design approach [41].  
Promising results have been reported, including the selective growth of bifidobacteria and 
lactobacilli and/or the formation of beneficial metabolites, such as short chain fatty acids. 
However, it should be noted that these studies are still limited to in vitro models or small 
scale animal or human trials [16, 17, 40]. For example, thermally produced resistant starch 
has been demonstrated to possess a bifidogenic and butyrogenic effect in an in vitro three 
stage continuous fermentation system inoculated with human feces [42]. Furthermore, this 
study suggested that resistant starch crystalline polymorphism, resulting from different 
thermal treatments, could convey different prebiotic effects on the human colon flora. 
3. Efficacy of prebiotics across the life span 
3.1. Methods to evaluate prebiotics 
Research into the efficacy of prebiotics includes a collection of methods currently in use, 
from pure cultures to human trials, which can be generally classified into in vivo and in vitro 
methods. Overall, the prebiotic effect is mainly evaluated by the presence of beneficial 
metabolites and measuring the growth of major bacterial groups commonly present in the 
human gut, in particular a selection for increased numbers of bifidobacteria and lactobacilli 
in comparison with undesirable bacteria such as certain clostridia and sulfate reducing 
bacteria [40]. Ultimately, health claims concerning prebiotic effects must rely on 
comprehensive well-controlled human trials. Thus, in vivo studies have evolved over the 
years to robust experimental designs which combine double blind and placebo-controlled 
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designs with advanced microbial analyses, such as bacterial enumeration using 16s DNA 
probes in fluorescence in situ hybridization (FISH) [16]. In most human studies, the 
production of short chain fatty acids (SCFA) has been quantified in fecal samples, as a 
marker of enhanced saccharolytic fermentation in response to prebiotic treatment [13]. 
In spite of their high significance, in vivo human studies are usually limited, mainly due to 
financial and ethical restrictions. Therefore, animal models have been used as a possible 
viable alternative to the human GI tract, while allowing the researchers to perform in vivo 
experiments in tightly controlled conditions as well as access intestinal contents, tissues and 
organs at autopsy. Moreover, many in vivo experiments have used germ-free animals dosed 
with fecal suspensions obtained from human donors, which are considered to be a reliable 
model for a reconstituted human gut flora. However, data generated from animal models do 
not necessarily coincide with human or in vitro studies, as has been shown for prebiotic 
resistant starch type III [42].  
Consequently, many in vitro experimental models have been developed to simulate various 
aspects of the human GI tract [43-45]. Seeking to closely mimic the conditions of organs 
along the GI tract, these models include a reactor or a series of reactors under tightly 
controlled settings, with the large intestine represented by an anaerobic reactor/s inoculated 
with fecal slurries [40]. Thus, these systems offer researchers a controlled experimental 
design that is relatively inexpensive, easy to set up, high throughput and raises minimal 
ethical issues [46]. 
One of the first in vitro GI models described in the literature was termed the simulator of the 
human intestinal microbial ecosystem (SHIME) [47]. This computer controlled model is 
composed of a five serially connected vessels simulating the conditions of the stomach, 
small intestine, ascending, transverse and descending colon [48, 49]. Operators can control 
various parameters of physiological relevance, including gastric and pancreatic secretions, 
pH, transit time, feed composition as well as sample different loci along the system on a 
regular basis [13, 46]. Another comprehensive in vitro GI model was developed in the 
Netherlands [50]. This model is actually comprised of two seperate parts: TIM-1 is a series of 
four computer controlled chambers simulating the upper GI, i.e. the stomach, duodenum, 
jejunum and ileum, while TIM-2 models the large intestine. Unlike the SHIME, this model 
consists of a series of linked glass vessels containing flexible walls, which allow simulation 
of the peristaltic movements of the GI. The hollow fiber membrane construct of the system 
enables to simulate absorption of water and nutrients in the lumen as well as their removal 
from the colon [13, 46]. Similarly, simple glass reactors have been used for in batch and three 
stage continuous fermentation systems to simulate the lower GI, i.e. the proximal, transverse 
and distal colon, and have been validated against sudden death victims [51]. 
Overall, in vivo methods and particularly human trials are essential for establishing health 
claims regarding prebiotic effects on human microflora. However, such methods are 
hindered by financial, ethical and practical reasons. In vitro models fail to fully mimic the GI 
system, particularly peristaltic movements, mucosal uptake and impact of immune 
components. Nevertheless, these systems offer relatively low costs, ease of use and have 
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minimal ethical considerations, while providing researchers controllable settings for 
studying luminal biochemistry and microbiology. 
3.2. Prebiotic efficacy in infancy and childhood 
At birth, the neonate gut is considered to be sterile with rapid colonization by bacteria 
believed to occur in three phases: delivery, breastfeeding and weaning to solid foods [52-54]. 
Immediately after birth, facultative anaerobic bacteria such as Enterobacteriaceae, streptococci 
and staphylococci colonize the gut environment of the newborn, gradually consuming 
oxygen and producing various metabolites. Consequently, strict anaerobic bacterial 
population dominated by bifidobacteria, Clostridium and Bacteroides can be established [55-
57]. Within the first year of life, the microflora is highly dynamic, but by the age of two years 
with the introduction of solid foods, the colonic microbiota is considered complete – it 
stabilizes and resembles that of the adult [58-60].  
The interest in prebiotics as a nutritional strategy to program infant gut microbiota to favor 
a more advantageous population has been inspired by the beneficial effects attributed to the 
200 different human milk oligosaccharides (HMO) [52-54]. Based on the observations of 
bifidobacteria in the feces of breastfed babies, attempts have been made to reproduce this 
bifidogenic aspect in infant formulas by adding commercial prebiotics, in particular FOS 
and GOS [8, 53]. This practical application of prebiotics was evaluated for example in 
double-blind, randomized and controlled studies in 90 full term infants, which 
demonstrated that 4 g/L or 8 g/L of FOS, GOS or their combination resulted in a significant 
decrease in fecal pH and a concomitant increase in bifidobacteria and lactobacilli after 28 
days feeding [61, 62]. A GOS and FOS mixture at a ratio of 9:1 (GOS:FOS) has been 
extensively studied as a prebiotic additive to infant formulas [63], and shown to increase 
bifidobacteria in infant feces and lower the incidence of pathogens [64-66]. Therefore, the 
administration of FOS and GOS into commercial infant formulas for their prebiotic effects 
has spread, and researchers continue exploring additional prebiotics as possible candidates 
for infant formulas supplementation. Moreover, studies are also looking into the persistence 
of the prebiotic effects. 
3.3. Prebiotic efficacy in adulthood 
To date, various studies have determined fructans (inulin and FOS) induce different 
beneficial effects on the health and general well-being of healthy adult subjects [10, 16-18]. A 
daily consumption of 5-10 g of fructans has been demonstrated to exert a bifidogenic effect 
on healthy adults based on dose-response studies, while similar doses of GOS and lactulose 
have been reported in in vitro and human trials as stimulating a bifidogenic effect [16, 67, 
68]. As to bowel habit, i.e. the frequency of bowel discharge but not fecal output, 
constipation and laxative effect, there is some evidence that in constipated subjects, inulin 
may increase bowel habit [69], whereas lactulose is prescribed at 20 g/day to increase fecal 
output of chronically constipated patients, however, having a bifidogenic effect on healthy 
adults at lower doses [68]. Moreover, numerous studies have shown that fecal output 
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remains unchanged at a daily intake of up to 15 g fructans with a slight increase at doses of 
15 g/day or higher [11]. Hence, inulin, FOS, GOS and lactulose may be defined as mild 
laxatives with adverse effects observed only at a consumption of over 20 g/day. 
Additionally, established prebiotics have been linked to protection against enteric infections, 
modification of the host immune response, production of short chain fatty acids, particularly 
butyrate, increased mineral absorption and even the reduced risk of colon cancer [10, 11, 14, 
16, 18]. Prebiotics efficacy has also been studied during pregnancy and lactation. These life 
periods are sometimes accompanied by irregular gastrointestinal activity, which can be 
improved by the consumption of dietary fibers and prebiotics [20]. Furthermore, gestational 
weight gain and postpartum weight retention have been suggested to be affected from 
prebiotics intake, since they modulate the gut microflora [5]. However, it is also important to 
note that the prebiotic effect has not been found to extend to neonates and infants, even 
when solely breast fed. 
3.4. Prebiotics efficacy in ageing 
At the old age, increased threshold for taste and smell as well as masticatory dysfunction 
can lead to a nutritionally imbalanced diet. In addition, various physiological functions 
deteriorate with age and may influence the absorption and/or metabolism of nutrients. 
Furthermore, the increased intake of drugs results in GI disturbances due to antibiotics 
undesired effect on indigenous bacteria in the host gut flora. Thus, changes in the GI tract, 
modification of diet and host immune system inevitably give rise to bacterial population 
alterations [70, 71]. In spite of the increasing proportion of the elderly in Western countries 
[72, 73], scarce data exists on the changes that occur in the intestinal microbiota during the 
ageing process and their possible health outcomes. Overall, an increase in facultative 
anaerobes and decrease in Bacteroides and bifidobacteria (total numbers as well as species 
diversity) have been reported [74]. 
Therefore, modulation of the colon microflora by the consumption of prebiotics is 
increasingly being studied as a potent, cost effective and natural way to improve the health 
and well-being of elderly people as well as reduce risks for various diseases [70, 71, 74]. FOS 
and GOS ingestion, as well as synbiotic preparations, were found to significantly increase 
the number of bifidobacteria at the expense of less beneficial microbiota in ageing 
individuals [6, 75-78]. In addition, a randomized, double-blind, controlled study with 74 
subjects aged 70 and over has indicated that prebiotic addition can improve the low noise 
inflammatory process frequently observed in this sensitive population [79]. 
4. Prebiotics as therapeutics 
4.1. Prebiotics therapeutic efficacy in human diseases 
It is now well documented that the bacteria microflora residing in the human GI has a role 
not only in promoting health but also in preventing some diseases [3, 80, 81]. Prebiotics 
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have been reported to protect against pathogenic gastrointestinal infections by promoting 
the growth of probiotics which help displace pathogens from the mucosa, producing 
antimicrobial agents and competing with pathogens on binding sites and nutrients [3]. In 
addition to in vitro data which supports this disease preventing effect of prebiotics [16, 
22], a human study on 140 infants has concluded that consumption of oligofructose and 
cereal significantly reduced events of fever, frequency of vomiting, regurgitation and 
abdominal discomfort [82]. Moreover, various studies have shown that prebiotics can 
beneficially affect patients with antibiotic-associated diarrhea, especially when it arises 
from C. difficile [11]. 
Prebiotics have also been reported to reduce the risk of colon cancer as a result of gut flora 
modulation [11, 14, 16-18]. Specifically, they support the metabolism of carcinogenic 
molecules and the secretion of short chain fatty acids to the lumen by the colon microbiota 
[83, 84]. Furthermore, human trials have demonstrated that inulin, FOS and scFOS 
beneficially affect colorectal cell proliferation and genotoxicity [17], hence the potential of 
prebiotics in prevention and treatment of colon cancer should be further explored.  
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's 
disease (CD), has also been researched as a possible target for prebiotics [11, 16, 17]. As 
mucosal communities significantly change in these diseases, prebiotics may be used in order 
to manipulate them. For example, patients fed 15 g per day of a prebiotic mixture composed 
of 7.5 g inulin and 7.5 g FOS for 2 weeks prior to colonoscopy, have had more than a 10-fold 
increase in bifidobacterial and eubacterial numbers in the mucosa of the proximal and distal 
colon [85]. Similarly, in a small open-label human trial, 10 patients with active ileum-colonic 
CD were fed 15 g FOS daily for 3 weeks, after which a significant reduction in the Harvey 
Bradshaw index of disease activity was observed as well as an increase of fecal 
bifidobacteria numbers [11]. 
4.2. Prospective therapeutic targets 
4.2.1. Obesity and the metabolic syndrome 
Increasing evidence linking gut flora to human health and diseases have inspired further 
research regarding the possible link between gut flora and obesity, which has led to the 
notion that prebiotics could be harnessed as potential therapeutic agents or management 
tools to prevent and treat obesity and the metabolic syndrome [4, 5, 7, 20, 52]. The metabolic 
syndrome is a cluster of metabolic abnormalities, including abdominal obesity, type 2 
diabetes mellitus and cardiovascular diseases [86, 87].  
Various studies have shown that prebiotic intervention decreased fat storage in white 
adipose tissues and in the liver, decreased hepatic insulin resistance as well as systemic 
inflammation in several nutritional (high-fat diet-fed) and genetic (ob/ob mice) obese rodents 
[88-95]. Some beneficial effects of fructans on BMI, fat mass and insulin resistance were also 
shown in the limited human trials conducted so far [95-98].  
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However, to date, the mechanisms underlying the complex role of gut microbiota in such 
conditions are largely unknown [1]. It has been reported that a lower number of 
bifidobacteria at birth is associated with overweight later in childhood [99], and in adults, 
the number of bifidobacteria is slightly lower in individuals with obesity than in lean 
subjects [100]. The number of these bacteria is also decreased in patients with type 2 diabetes 
mellitus compared with nondiabetic people [101]. Hence, these results seem to suggest that 
bifidobacteria affects the development of obesity and its related comorbidities [52]. 
A remarkable increase has been observed in the number of Bifidobacterium spp. following 
inulin-type fructans supplementation to mice with diet-induced or genetically determined 
obesity [52]. Interestingly, the number of bifidobacteria was inversely correlated with the 
development of fat mass, glucose intolerance and levels of lipopolysaccharides (LPS) [102]. 
LPS has been found at a significantly higher level in the serum of obese individuals, which 
creates a metabolic endotoxemia, leading to obesity, insulin resistance and systemic 
inflammation [103]. Moreover, it has been reported that the overexpression of numerous 
host genes that are related to adiposity and inflammation was prevented by prebiotic 
intake [52]. 
A pathway involving short chain fatty acids (SCFA) has been proposed to be involved in the 
interplay between prebiotics, the gut flora and obesity. SCFA act as signaling molecules and 
are specific ligands for at least two G protein-coupled receptors, GPR41 and GPR43, which 
have a potential role in fat mass development [13, 104]. In addition, it has been shown that 
acetate and propionate can modify hepatic lipid metabolism [105]. Interestingly, a recent 
study has demonstrated that diet-induced obesity and insulin resistance were prevented 
when mice on a high-fat diet were supplemented with butyrate, which promoted energy 
expenditure and induced mitochondrial function [106]. Various studies have shown that a 
diet enriched with prebiotics leads to a greater intestinal SCFA production and thereby 
migitates body weight gain, fat mass development and the severity of diabetes [89, 90, 100, 
107-109]. Numerous peptides secreted by the enteroendocrine cells along the GI are 
involved in the regulation of energy homeostasis and/or pancreatic function. Three such 
peptides which can modulate food intake and energy expenditure are glucagon-like 
peptide-1 (GLP-1), peptide YY (PYY) and ghrelin [110-113]. Thus, it has been suggested that 
SCFA are related to changes in the gut peptide secretion, namely increased production and 
secretion of GLP-1 and PYY and the reduction of ghrelin which induce metabolic effects [13, 
114, 115]. Piche et al. were the first to report that inulin-type fructan feeding of 20 g/day 
significantly increased plasma GLP-1 in humans [116]. In another study, a 2-week 
supplementation with inulin-type fructans (16 g/day) to healthy volunteers increased GLP-1, 
consequently increasing satiety, lowering calorie intake and decreasing postprandial 
glycemia [90, 108]. Furthermore, prebiotic treatment in obese patients has been found to 
induce and increase PYY and decrease ghrelin levels [117]. Finally, Tarini and Wolever have 
demonstrated that a single dose of inulin significantly increased postprandial plasma GLP-1 
and decreased plasma ghrelin [118]. This is in contrast to perceived necessity for a 
prolonged prebiotics administration to modulate gut microbiota and allow effect on gut 
endocrine function. Thus, it seems that further studies are needed to fully unravel the 
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potential of prebiotics to offer a nutritional means to cope with the worrisome increase in 
human obesity and the metabolic syndrome.   
5. Future challenges 
5.1. Harmonization of methods to evaluate efficacy 
To date, a plethora of studies have investigated the effects of prebiotics on human health 
and well-being, leading to the general realization prebiotics could serve as a possible 
method of therapeutic intervention. However, the majority of these studies cannot be 
compared due to the variety of methods employed. For example, results obtained by 
bacterial isolation techniques [39, 119] cannot be compared with data from more advanced 
methods for the molecular characterization of the microbiota, now considered essential to 
obtain a comprehensive view of the gut ecosystem. Furthermore, DNA-based techniques 
including the use of the 16s ribosomal RNA gene are considered as less biased, hence their 
results are more reliable [54]. In addition, studies focused on the effect of prebiotics on the 
elderly, even in healthy subjects, lack a clear definition of 'elderly', and various groups are 
recruited, usually on the basis of 'over 60' [120], 'over 65' [119, 121] or 'over 70' [122]. This 
makes is difficult to define a 'threshold age' at which the gut environment starts to be 
influenced from the ageing process [70]. Thus, harmonization of methods to evaluate 
efficacy is a prequisite step limiting the further application of prebiotics for the prevention 
and treatment of diseases as well as the development of novel prebiotics. 
5.2. The challenge of personalization 
A broad range of parameters has been known to affect the bacterial composition of the 
infant gut, e.g. mode of delivery, type of feeding (exclusive breastfeeding versus formula), 
antibiotic use and maternal infection [55-57, 123, 124]. Furthermore, various studies have 
indicated that the low number of certain bacteria at birth such as bifidobacteria is related to 
overweight later in childhood [99]. Consequently, prebiotics supplementation even in 
infants may be used as a preventive nutritional programming tool, which will affect the 
health and well-being also in adulthood. Moreover, it has been increasingly accepted that 
environmental factors such as nutritional habits and lifestyle may impact the gut microbiota 
composition, for example striking country-related differences in the effects of age on the 
microflora have been reported [70]. This wide variety of factors, affecting intestinal 
microbiota composition from infancy to elderly, drove the need for personalized nutrition, 
including personalized and tailored prebiotics. In addition, since prebiotics are recently 
considered even as therapeutic agents for the prevention and treatment of diseases, it may 
be beneficial to aim personalized prebiotics to people at high-risk to develop these illnesses. 
Thus, the challenge of personalization includes performing long-term, large-sized, well-
controlled and multidisciplinary-collaborated studies which will demonstrate and establish 
the health promoting effects of prebiotics and enable harnessing them in the clinic or in 
supermarket shelves. 
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6. Conclusions 
Prebiotics have emerged as cost-effective and efficient nutritional programming tools to 
beneficially and selectively promote the growth and/or activity of certain bacteria in the 
indigenous flora of the human GI. So far, prebiotics have been demonstrated to exert 
various beneficial effects during an individual's lifetime, from infancy to ageing, as well as 
function as therapeutic agents for the prevention and treatment of different diseases, 
including obesity and the metabolic syndrome.  
In addition to the well-established prebiotics of FOS, GOS and lactulose, novel prebiotics are 
constantly being developed. State of the art techniques, in vitro gastrointestinal models and 
advanced computerization tools are leading many researchers to adopt more complete and 
comprehensive approaches, e.g. metabolomics and metagenomics.  
Future challenges include the harmonization of methods of evaluating efficacy that will help 
focus research efforts and enable a more comprehensive understanding of prebiotic 
mechanisms of action and beneficial effects and how these can be modulated. Another 
important prospect is personalization, i.e. fitting tailored prebiotics to individual needs in 
order to nutritionally program and affect their health and well-being from infancy and into 
old and prosperous age. 
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